Prestige Consumer Healthcare (NYSE:PBH) Sets New 1-Year High at $75.31

Prestige Consumer Healthcare Inc. (NYSE:PBH)’s stock price reached a new 52-week high during mid-day trading on Wednesday . The stock traded as high as $75.31 and last traded at $75.18, with a volume of 124587 shares traded. The stock had previously closed at $74.09.

Analyst Upgrades and Downgrades

Several research firms have issued reports on PBH. StockNews.com downgraded Prestige Consumer Healthcare from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, May 21st. DA Davidson increased their price objective on Prestige Consumer Healthcare from $93.00 to $95.00 and gave the stock a “buy” rating in a research report on Wednesday, August 28th. Finally, Canaccord Genuity Group reiterated a “buy” rating and issued a $80.00 price objective on shares of Prestige Consumer Healthcare in a research report on Tuesday, May 21st. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $98.75.

Prestige Consumer Healthcare Stock Down 1.0 %

The company has a debt-to-equity ratio of 0.65, a current ratio of 3.23 and a quick ratio of 1.90. The company has a market capitalization of $3.68 billion, a P/E ratio of 17.98, a PEG ratio of 2.11 and a beta of 0.48. The company has a 50 day moving average of $70.18 and a 200-day moving average of $69.41.

Prestige Consumer Healthcare (NYSE:PBH) last posted its earnings results on Thursday, August 8th. The company reported $0.90 earnings per share for the quarter, topping analysts’ consensus estimates of $0.86 by $0.04. Prestige Consumer Healthcare had a return on equity of 12.55% and a net margin of 18.43%. The firm had revenue of $267.10 million for the quarter, compared to the consensus estimate of $260.54 million. During the same quarter in the prior year, the business earned $1.06 EPS. The business’s revenue for the quarter was down 4.4% on a year-over-year basis. As a group, equities analysts anticipate that Prestige Consumer Healthcare Inc. will post 4.42 EPS for the current year.

Hedge Funds Weigh In On Prestige Consumer Healthcare

Hedge funds and other institutional investors have recently modified their holdings of the company. Congress Asset Management Co. MA increased its stake in Prestige Consumer Healthcare by 596.2% in the 4th quarter. Congress Asset Management Co. MA now owns 679,256 shares of the company’s stock worth $41,584,000 after buying an additional 581,685 shares in the last quarter. Norges Bank purchased a new position in shares of Prestige Consumer Healthcare during the fourth quarter valued at about $27,739,000. Ariel Investments LLC grew its position in shares of Prestige Consumer Healthcare by 10.7% during the second quarter. Ariel Investments LLC now owns 2,835,203 shares of the company’s stock valued at $195,204,000 after purchasing an additional 274,212 shares in the last quarter. Allspring Global Investments Holdings LLC grew its position in shares of Prestige Consumer Healthcare by 26.0% during the second quarter. Allspring Global Investments Holdings LLC now owns 1,320,125 shares of the company’s stock valued at $90,891,000 after purchasing an additional 272,773 shares in the last quarter. Finally, Victory Capital Management Inc. grew its position in shares of Prestige Consumer Healthcare by 9.0% during the second quarter. Victory Capital Management Inc. now owns 2,074,460 shares of the company’s stock valued at $142,827,000 after purchasing an additional 171,357 shares in the last quarter. 99.95% of the stock is owned by institutional investors.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.